T
13.48
0.88 (6.98%)
| Penutupan Terdahulu | 12.60 |
| Buka | 12.89 |
| Jumlah Dagangan | 2,307,590 |
| Purata Dagangan (3B) | 1,331,543 |
| Modal Pasaran | 1,031,105,408 |
| Harga / Jualan (P/S) | 7.06 |
| Harga / Buku (P/B) | 76.10 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2024 - 11 Nov 2024 |
| Margin Keuntungan | -172.75% |
| Margin Operasi (TTM) | -89.07% |
| EPS Cair (TTM) | -4.52 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 69.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2,662.08% |
| Nisbah Semasa (MRQ) | 1.71 |
| Aliran Tunai Operasi (OCF TTM) | -272.23 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -214.69 M |
| Pulangan Atas Aset (ROA TTM) | -26.14% |
| Pulangan Atas Ekuiti (ROE TTM) | -279.94% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Travere Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
-0.5
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.0 |
| Purata | -0.50 |
|
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.65% |
| % Dimiliki oleh Institusi | 99.13% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 27.00 (Scotiabank, 100.30%) | Beli |
| 27.00 (Wells Fargo, 100.30%) | Beli | |
| Median | 24.50 (81.75%) | |
| Rendah | 20.00 (Barclays, 48.37%) | Beli |
| Purata | 24.00 (78.04%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 17.93 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 14 Nov 2024 | 22.00 (63.20%) | Pegang | 18.47 |
| Barclays | 01 Nov 2024 | 20.00 (48.37%) | Beli | 17.57 |
| Scotiabank | 01 Nov 2024 | 27.00 (100.30%) | Beli | 17.57 |
| 16 Oct 2024 | 23.00 (70.62%) | Beli | 18.05 | |
| Wells Fargo | 21 Oct 2024 | 27.00 (100.30%) | Beli | 18.10 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| INRIG JULA | - | 18.79 | -2,506 | -47,197 |
| Jumlah Keseluruhan Kuantiti Bersih | -2,506 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -47,197 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 18.79 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| INRIG JULA | Pegawai | 06 Jan 2025 | Jual automatik (-) | 440 | 18.71 | 8,232 |
| INRIG JULA | Pegawai | 03 Jan 2025 | Jual (-) | 2,066 | 18.86 | 38,965 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |